Rucaparib Maintenance Therapy Improved Progression-Free Survival Among Patients With Recurrent or Metastatic Endometrial Cancer
Featuring Bradley Corr, MD
At the Society for Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancers, Bradley Corr, MD, Anschutz Medical Campus at Colorado University, Aurora, Colorado, shared results from a phase 2 study evaluating rucaparib maintenance therapy for metastatic or recurrent endometrial cancer.
This study found, when compared to placebo, rucaparib maintenance therapy improved the progression-free survival in a statistically significant and clinically meaningful manner for these patients.
Source:
Corr B, Haggerty A, Gysler SM, et al. A phase II, randomized, double-blind study of the use of rucaparib versus placebo maintenance therapy in metastatic and recurrent endometrial cancer. Presented at Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers; March 16-18, 2024. San Diego, California.